Archive Adhoc- and Press releases 2014

ENGLISH DEUTSCH
15 October 2014
PM: WILEX publishes 9-month Financial Report 2014
14 October 2014
AH: WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche
PM: WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche
18 September 2014
PM: UCB waives repayment of shareholder loan to WILEX
15 July 2014
PM: WILEX publishes Half-yearly Financial Report 2014
15 July 2014
PM: WILEX AG successfully completes capital reduction
30 June 2014
AH: WILEX and RedHill Biopharma enter into an exclusive license agreement for MESUPRON®
PM: WILEX and RedHill Biopharma enter into an exclusive license agreement for MESUPRON®
21. Mai 2014
AH: WILEX returns rights from collaboration in oncology to UCB and UCB waives repayment of the shareholder loan
30 April 2014
AH: WILEX and IBA terminate marketing partnership – Global rights to REDECTANE® diagnostic agent revert to WILEX
14 April 2014
PM: WILEX published 3-Month Financial Report 2014
10 April 2014
AH: WILEX AG plans reduction of share capital
31 March 2014
PM: WILEX announces financial figures for the 2013 financial year and reports on course of business
28 March 2014
AH: WILEX enters into licensing and development partnership for MESUPRON® in China with Link Health Group
PM: WILEX enters into licensing and development partnership for MESUPRON® in China with Link Health Group
25 March 2014
PM: WILEX will publish the financial results and the Annual Report 2013 on March 31, 2014
24 February 2014
AH: Professor Olaf G. Wilhelm leaves the Executive Management Board on 31 March 2014, Dr Jan Schmidt-Brand will lead the Company
PM: Professor Olaf G. Wilhelm leaves the Executive Management Board on 31 March 2014, Dr Jan Schmidt-Brand will lead the Company
29 January 2014
AH: WILEX AG plans extensive cost-cutting measures
PM: WILEX AG plans extensive cost-cutting measures
Seite gelesen: 447 | Heute: 2